Exelixis Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Exelixis Inc (EXEL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $16.89 per share for the 12-month period ending 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2020-02-25
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-29 was $14.32, a 18.94% increase year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-30 was $12.04, a 66.53% increase year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $7.23, a 121.78% increase year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $3.26, a 21.07% decline year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $16.89, a 7.51% increase from fiscal 2018.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $15.71, a 94.19% increase from fiscal 2017.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2017 was $8.09, a 73.23% increase from fiscal 2016.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $4.67, a 27.25% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2020-01-03 | $16.89 10-K · filed 2020-02-25 | ||||
| 2019-09-27 | $16.76 10-Q · filed 2019-10-30 | ||||
| 2019-06-28 | $15.32 10-Q · filed 2019-07-31 | ||||
| 2019-03-29 | $14.32 10-Q · filed 2019-05-01 | ||||
| 2018-12-28 | $15.71 10-K · filed 2019-02-22 | ||||
| 2018-09-28 | $14.40 10-Q · filed 2018-11-01 | ||||
| 2018-06-29 | $15.20 10-Q · filed 2018-08-01 | ||||
| 2018-03-30 | $12.04 10-Q · filed 2018-05-02 | ||||
| 2017-12-29 | $8.09 10-K · filed 2018-02-26 | ||||
| 2017-09-30 | $8.14 10-Q · filed 2017-11-01 | ||||
| 2017-06-30 | $7.27 10-Q · filed 2017-08-02 | ||||
| 2017-03-31 | $7.23 10-Q · filed 2017-05-01 | ||||
| 2016-12-31 | $4.67 10-K · filed 2017-02-27 | ||||
| 2016-09-30 | $4.67 10-Q · filed 2016-11-03 | ||||
| 2016-06-30 | $4.32 10-Q · filed 2016-08-03 | ||||
| 2016-03-31 | $3.26 10-Q · filed 2016-05-04 | ||||
| 2015-12-31 | $3.67 10-K · filed 2016-02-29 | ||||
| 2015-09-30 | $3.67 10-Q · filed 2015-11-10 | ||||
| 2015-06-30 | $4.72 10-Q · filed 2015-08-11 | ||||
| 2015-03-31 | $4.13 10-Q · filed 2015-04-30 | ||||
| 2014-12-31 | $5.34 10-K · filed 2015-03-02 | ||||
| 2014-09-30 | $5.53 10-Q · filed 2014-11-04 | ||||
| 2014-06-30 | $5.52 10-Q · filed 2014-07-31 | ||||
| 2014-03-31 | $5.73 10-Q · filed 2014-05-01 | ||||
| 2013-12-31 | $5.27 10-K · filed 2015-03-02 | ||||
| 2013-09-30 | $6.42 10-Q · filed 2013-10-30 | ||||
| 2013-06-30 | $6.47 10-Q · filed 2013-08-06 | ||||
| 2013-03-31 | $6.38 10-Q · filed 2013-05-07 | ||||
| 2012-12-31 | $5.88 10-K · filed 2015-03-02 | $7.28 10-K · filed 2013-02-21 | |||
| 2012-09-30 | $7.92 10-Q · filed 2012-11-07 | ||||
| 2011-12-31 | $6.22 10-K · filed 2014-02-20 | $9.79 10-K · filed 2013-02-21 | |||
| 2010-12-31 | $7.35 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |